Balar AV et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: Results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2023;34(3):289-99. Abstract
Bamias A et al. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the phase III IMvigor130 study. Genitourinary Cancers Symposium 2023;Abstract LBA441.
Basile G et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res 2022;28(23):5107-14. Abstract
Daneshmand S et al. First results from SunRISe-1 in patients with BCG unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone. AUA 2023;Abstract LBA02-03.
Daneshmand S et al. Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis. Genitourinary Cancers Symposium 2023;Abstract 504.
Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;40(7):344.e1-9. Abstract
Funt SA et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial. J Clin Oncol 2022;40(12):1312-22. Abstract
Galsky MD et al. Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma: Final overall survival analysis from the phase 3 IMvigor130 study. Genitourinary Cancers Symposium 2023;Abstract LBA440.
Galsky MD et al. Extended follow-up results from the CheckMate 274 trial. Genitourinary Cancers Symposium 2023;Abstract LBA443.
Galsky MD et al. Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients with HER2-expressing urothelial carcinoma (UC). ASCO 2022;Abstract 438.
Grande E et al. Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the Imvigor130 OS final analysis. ASCO 2023;Abstract 4503.
Grivas P et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. Genitourinary Cancers Symposium 2022;Abstract 434.
Gupta S et al. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. ASCO 2023;Abstract 4505.
Hoimes CJ et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol 2023;41(1):22-31. Abstract
Hoimes C et al. Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304. Genitourinary Cancers Symposium 2023;Abstract TPS588.
Kulkarni GS et al. Pembrolizumab in participants with bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: 5-year follow-up from cohort A of the phase 2 KEYNOTE-057 trial. Society of Urologic Oncology 2022;Poster 188.
Lerner SP et al. SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. ASCO 2023;Abstract 4508.
Loriot Y et al. Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). ASCO 2023;Abstract LBA4619.
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. ASCO 2023;Abstract LBA3000.
Neechi A et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guérin: Results from cohort B of the phase 2 KEYNOTE-057 trial. Genitourinary Cancers Symposium 2023;Abstract LBA442.
Petrylak DP et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Genitourinary Cancers Symposium 2023;Abstract 520.
Petrylak DP et al. Study EV-103 cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. Genitourinary Cancers Symposium 2022;Abstract 435.
Pfister C et al. Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. ASCO 2023;Abstract LBA4507.
Powles T et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. Genitourinary Cancers Symposium 2022;Abstract 487.
Psutka SP et al. SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy. Genitourinary Cancers Symposium 2023;Abstract TPS584.
Rosenberg JE et al. Durvalumab plus olaparib in previously unthreatened, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU). J Clin Oncol 2023;41(1):43-53. Abstract
Rosenberg JE et al. Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. ASCO 2023;Abstract 4516.
Rosenberg JE et al. Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.
Sheng X et al. Primary results of a phase Ib/II combination study of RC48-ADCV, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma (LA/mUC). ASCO 2023;Abstract 4518.
Sheng X et al. RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. ASCO 2022;Abstract 4520.
Siefker-Radtke AO et al. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. ASCO 2023;Abstract 4504.
Siefker-Radtke AO et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract
Szabados B et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 2022;82(2):212-22. Abstract
Tagawa ST et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan in patients with metastatic urothelial cancer who progressed after platinum-based chemotherapy and a checkpoint inhibitor. Genitourinary Cancers Symposium 2023;Abstract 526.
van Valenberg FJP et al. Safety, tolerability, and preliminary efficacy of TAR-200 in intermediate-risk non-muscle-invasive bladder cancer patients: A phase 1 study. Genitourinary Cancers Symposium 2023;Abstract 505.
Xu H et al. A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. ASCO 2022;Abstract 4519.